New Intra-articular Therapy for Osteoarthritis


Andrew Marino, Ph.D. Oleg V. Kolomytkin, Ph.D. David D. Waddell, M.D.

Orthopedic Specialist Research LSU Medical School Shreveport, Louisiana


Summary

- Background
- In vitro study
- Animal study
- Clinical studies
- Future plans

Factors Involved in Osteoarthritis



American College of Rheumatology 2000 Guidelines



Surgery


Advantages of Local Treatment

- OA is a local disease
- Local therapy avoids systemic adverse events (COX II side-effects)
- Lower doses of therapeutic agents


Osteoarthritis Local Therapies

- Intra-articular steroids
- Hyaluronans
- Transdermal non-steroidal agents
- New agents?

Background of Laboratory Research



Late Events (2-48 hrs) MMPs \rightarrow OA



Proposed Membrane-Channel Research

Basic Idea \mapsto Pathological changes in specific ion channels mediate progression of OA


Identify the channels functionally by
Comparing OA and normal synovial cells

2) Design chemical agents to block the altered channels


Plan

Inject blockers that are already on the market for heart problems

Surgical Biopsy Procedure



In Vitro Study: Effect of Calcium-Channel Blocker Verapamil on MMP Production



IL-1ß +

100 µM

Verapamil

IL-1ß +

10 µM

Verapamil

50

0

Control

IL-1ß

50

0

Control

IL-1ß

IL-1ß +

10 µM

Verapamil

IL-1ß +


100 µM

Verapamil

Animal Safety Study: Mouse Verapamil Study Animals: BALB/c 3, 6 months old 0.4-2.5 μg/10 μL (≤100 μM) Dose: Injection Site: Knee (intra-articular) Recovery 4 hrs, 24 hrs, 4 days Times: Endpoint: Inflammation

Zeuner, Arthritis Rheum. <u>46</u>: 2219, 2002

Histological Evaluation



- Mid-saggital plane used for evaluation
- Inflammation scale 0-3
- Scoring by blinded observer (pathologist)


Mouse Study Results

Results at Specific Time Points

	<u>4 Hours</u>		<u>1 Day</u>		<u>4-5 Days</u>	
Histological Score	<u>0-1</u>	<u>2-3</u>	<u>0-1</u>	<u>2-3</u>	<u>0-1</u>	<u>2-3</u>
Verapamil	5	1	5	1	3	1
Control	1	3	1	3	3	1


Overall Result


Histological Score	<u>0-1</u>	<u>2-3</u>	OR = 6.1
Verapamil	13	3	P < 0.05
Control	5	7	1 - 0.00





Open Study Evaluating Verapamil in Osteoarthritis of the Knee

IRB LSUHSC-S Study Design Open study (no contemporaneous control) Principal Investigator David Waddell, M.D. Other Investigators None Dose 0.2 mg & 0.5 mg Inclusion CriteriaKellgren-Lawrence grade 4 Study Hypothesis Symptomatic treatment of OA pain Study Endpoints WOMAC, Physician VAS, Patient VAS Follow-up Schedule1, 2, 3, 4, 5, 16, 20 weeks











Verapamil Study No. 1 (0.2 mg) % Decrease in WOMAC




 $\frac{\text{%Decrease} = \frac{\text{score at } t = 0 - \text{score at } t}{\text{score at } t = 0} \times 100}{\text{score at } t = 0}$


Verapamil Study No. 1 (0.2 mg) % Decrease in Physician VAS





Verapamil Study No. 1 (0.2 mg) % Decrease in Patient VAS





%Decrease=	score at $t=0$ - score at t	x100
	score at $t=0$	<u> </u>













Verapamil Study No. 2 (0.5 mg) % Decrease in WOMAC




%Decrease =	score at $t=0$ - score at t x_{100}
	$\frac{1}{100}$ score at t=0

Verapamil Study No. 2 (0.5 mg) % Decrease in Physician VAS



Verapamil Study No. 2 (0.5 mg) % Decrease in Patient VAS



 $\% Decrease = \frac{score at t = 0 - score at t}{score at t = 0} x100$

Verapamil Study Summary of Results

- Pilot study
- 25 patients
- Experienced physician
- ALL data points shown
- All 3 efficacy tools suggest positive results

Pertinent Clinical Facts:

- Most hyaluronans are tested in patients with Kellgren-Lawrence Grade 2 and 3 disease.
- Pilot study showed efficacy of verapamil in knees that were mostly Kellgren-Lawrence Grade 4.

Important Features of the Verapamil Treatment

- Single-injection local therapy for a local disease.
- No adverse events noted in the 25-patient pilot study (no blood-pressure changes, flares, or other complications).
- Animal study indicates Verapamil is safe for intra-articular injection.
- Proposed treatment is rationally grounded.
- Verapamil is generally recognized as safe.

What is the Market Looking For?

- A single-injection therapy for osteoarthritis has many benefits.
- Physicians and patients prefer simplified therapies.
- One injection q 3-4 months


Single Injection of Verapamil for the Treatment of Osteoarthritis

- Local therapy for local symptoms
- Local therapy avoids systemic adverse events.
- Verapamil is technically easier to inject than ANY hyaluronan.


Verapamil Composition

Are anti-inflammatory effects of verapamil and Synvisc additive?


Effects of Synvisc and Verapamil are Additive Synvisc Concentration 2 mg/mL




Effects of Synvisc and Verapamil are Additive Synvisc Concentration 4 mg/mL




Effects of Synvisc and Verapamil are Additive Synvisc Concentration 8 mg/mL



Compatibility of Verapamil and Synvisc Effect of Synvisc on Verapamil



Compatibility of Verapamil and Synvisc Effect of Verapamil on Synvisc



Open Study Evaluating Verapamil Plus Synvisc in Osteoarthritis of the Knee

IRB LSUHSC-S

Study Design Open study (no contemporaneous control)

Principal Investigator David Waddell, M.D.

Other Investigators None

Study LocationOSL


Dose 0.5 mg Verapamil + Synvisc, x3


Inclusion CriteriaOA-IV


Study HypothesisSymptomatic treatment of OA pain


Study Endpoints WOMAC, Physician VAS, Patient VAS

Follow-up Schedule 1, 2, 3, 4, 5, 16, 20 weeks









Effect of Verapamil on Flare Probability

Patient	No. of Previous <u>Courses</u>	No. of Injections Verapamil/ <u>Synvisc</u>	Injection-Wise Probability <u>of a Flare</u>	
1 (3-1)	2	1	0.08	
2 (3-2)	1	1	0.06	
3 (3-3)	1	1	0.06	Number of knee injected: 35
4 (3-4)	1	1	0.06	Number of flares: 0
5 (3-5)	1	1	0.06	Number of mares. O
6 (4-1)	2	3	0.08, 0.01, 0.005	
7 (4-2)	2	3	0.08, 0.01, 0.005	Probability of at least one
8 (4-3)	1	3	0.06, 0.02, 0.01	flare in 35 injections in
9 (4-4)	1	3	0.06, 0.02, 0.01	absence of Verapamil: 78%
10 (4-5)	3	3	0.10, 0.03, 0.03	
11 (4-6)	1	3	0.06, 0.02, 0.01	
12 (4-7)	2	3	0.08, 0.01, 0.005	
13 (4-8)	3	2	0.10, 0.03	
14 (4-9)	1	3	0.06, 0.02, 0.01	
15 (4-10)	1	3	0.06, 0.02, 0.01	
16 (4-11)	3	1	0.10	-
		Mean Probability	0.041	

U.S. Patents Pending

- U.S. Patent Application No. 11/138,738 COMPOSITIONS FOR TREATING OSTEOARTHRITIS
- U.S. Patent Application No. 11/138,744 METHODS FOR TREATING OSTEOARTHRITIS

Future Plans

Pilot studies show:

- strong positive evidence that a single injection of verapamil is therapeutic in the treatment of osteoarthritis, and
- (2) addition of verapamil to Synvisc may block the flare.

Appropriate clinical studies that capitalize on these findings are warranted.